With the current biotherapeutic market dominated by antibody molecules, bispecific
antibodies represent a key component of the next-generation of antibody therapy. Bispecific …

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …

One of the most effective molecular diversity techniques is phage display. This technology is
based on a direct linkage between phage phenotype and its encapsulated genotype, which …

Antibodies and antibody-derived molecules are continuously developed as both therapeutic
agents and key reagents for advanced diagnostic investigations. Their application in these …

Monoclonal antibodies (mAbs) and antibody fragments represent the most important
biopharmaceutical products today. Because full length antibodies are glycosylated …

Since the development of antibody-production techniques, a number of immunoglobulins
have been developed on a large scale using conventional methods. Hybridoma technology …

As a common expression host, Escherichia coli has received more and more attention due
to the recently developed secretory expression system, which offers advantages like …

Immunoassays are reliable, efficient, and accurate methods for the analysis of small‐
molecule harmful substances (such as pesticides, veterinary drugs, and biological toxins) …

Main reasons to produce recombinant proteins in the periplasm of E. coli rather than in its
cytoplasm are to-i-enable disulfide bond formation,-ii-facilitate protein isolation,-iii-control …

Currently, antibodies play major role in treating a wide variety of human diseases (eg,
cancer, viral infection, inflammation). Those pharmaceutic antibodies have become major …